{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:06:09Z","timestamp":1759824369086,"version":"3.41.2"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81300252","82070765"],"award-info":[{"award-number":["81300252","82070765"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Apolipoprotein E (APOE) loci, including rs429358 (\u01904) and rs7412 (\u01902), are involved in cardiovascular (CV) health. However, their effect on the CV-protective effect of aspirin remains unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 515 aspirin-treated individuals with existing CV diseases were recruited, and their APOE genotypes, platelet functions and other routine laboratory parameters were assessed when they enrolled. The first major CV events (myocardial infarction, stroke, revascularisation and CV death) and all CV events (major CV events plus unstable angina and transient ischaemic attack) during a mean 5.2-year follow-up period were recorded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After adjusting for age, gender, BMI, lifestyle, lipid profiles and other CV drugs and comorbidities, \u01902 carriers were found to exhibit ~80% lower risk of major CV and 60% lower risk of all CV (HR\u2009=\u20090.186, CI: 0.048\u20130.715, P\u2009=\u20090.014; HR\u2009=\u20090.435, CI: 0.234\u20130.812, P\u2009=\u20090.009, respectively) than \u01902 noncarriers. Furthermore, high incidence of high platelet reactivity assessed by arachidonic acid-induced light transmission aggregometry (23.4 vs. 13.7%, P\u2009=\u20090.038), triglyceride and haemoglobin and low low-density lipoprotein were observed. \u01904 carriers had slightly increased cholesterol and hypercholesterolemia incidence relative to \u01904 noncarriers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results demonstrated that APOE*\u01902 carriers can derive additional CV benefit from long-term aspirin treatment. Moreover, it was observed that APOE2 interacts with cyclooxygenase-1 (COX-1) and upregulates its activity. The CV-protective effect of aspirin in \u01902 carriers is likely attributed to APOE2 upregulating vascular COX-1-mediated CV protective pathway, together with aspirin partially inhibiting platelet COX-1-mediated platelet aggregation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ageing\/afac119","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T11:20:08Z","timestamp":1651836008000},"source":"Crossref","is-referenced-by-count":2,"title":["Apolipoprotein E*\u01902 carriers exhibit high aspirin-treated platelet reactivity and low cardiovascular risk during long-term aspirin treatment"],"prefix":"10.1093","volume":"51","author":[{"given":"Xiao-Li","family":"Li","sequence":"first","affiliation":[{"name":"Department of the Eighth Healthcare , Second Medical Center, National Clinical Research Center for Geriatric Diseases, , Beijing 1000853, China"},{"name":"Chinese People\u2019s Liberation Army General Hospital , Second Medical Center, National Clinical Research Center for Geriatric Diseases, , Beijing 1000853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University People's Hospital , Beijing 100044, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Dong","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of the Eighth Healthcare , Second Medical Center, National Clinical Research Center for Geriatric Diseases, , Beijing 1000853, China"},{"name":"Chinese People\u2019s Liberation Army General Hospital , Second Medical Center, National Clinical Research Center for Geriatric Diseases, , Beijing 1000853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Jun","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of the Eighth Healthcare , Second Medical Center, National Clinical Research Center for Geriatric Diseases, , Beijing 1000853, China"},{"name":"Chinese People\u2019s Liberation Army General Hospital , Second Medical Center, National Clinical Research Center for Geriatric Diseases, , Beijing 1000853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of the Eighth Healthcare , Second Medical Center, National Clinical Research Center for Geriatric Diseases, , Beijing 1000853, China"},{"name":"Chinese People\u2019s Liberation Army General Hospital , Second Medical Center, National Clinical Research Center for Geriatric Diseases, , Beijing 1000853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of the Eighth Healthcare , Second Medical Center, National Clinical Research Center for Geriatric Diseases, , Beijing 1000853, China"},{"name":"Chinese People\u2019s Liberation Army General Hospital , Second Medical Center, National Clinical Research Center for Geriatric Diseases, , Beijing 1000853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Qing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of the Eighth Healthcare , Second Medical Center, National Clinical Research Center for Geriatric Diseases, , Beijing 1000853, China"},{"name":"Chinese People\u2019s Liberation Army General Hospital , Second Medical Center, National Clinical Research Center for Geriatric Diseases, , Beijing 1000853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of the Eighth Healthcare , Second Medical Center, National Clinical Research Center for Geriatric Diseases, , Beijing 1000853, China"},{"name":"Chinese People\u2019s Liberation Army General Hospital , Second Medical Center, National Clinical Research Center for Geriatric Diseases, , Beijing 1000853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"2022060112333135300_ref1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.arcmed.2015.06.006","article-title":"Global overview of the epidemiology of atherosclerotic cardiovascular disease","volume":"46","author":"Barquera","year":"2015","journal-title":"Arch Med Res"},{"key":"2022060112333135300_ref2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists' Collaboration","year":"2002","journal-title":"BMJ"},{"key":"2022060112333135300_ref3","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1161\/CIRCULATIONAHA.109.900589","article-title":"Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization","volume":"120","author":"Frelinger","year":"2009","journal-title":"Circulation"},{"key":"2022060112333135300_ref4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","article-title":"Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention","volume":"35","author":"Aradi","year":"2014","journal-title":"Eur Heart J"},{"key":"2022060112333135300_ref5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000342489","article-title":"Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with cardiovascular disease","volume":"59","author":"Fan","year":"2013","journal-title":"Gerontology"},{"key":"2022060112333135300_ref6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.atherosclerosis.2008.04.016","article-title":"Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse","volume":"202","author":"McClelland","year":"2009","journal-title":"Atherosclerosis"},{"key":"2022060112333135300_ref7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MOL.0000000000000540","article-title":"Lipid-driven immunometabolic responses in atherosclerosis","volume":"29","author":"Gister\u00e5","year":"2018","journal-title":"Curr Opin Lipidol"},{"key":"2022060112333135300_ref8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.atherosclerosis.2016.10.037","article-title":"Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: a review","volume":"255","author":"Rasmussen","year":"2016","journal-title":"Atherosclerosis"},{"key":"2022060112333135300_ref9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pathol.2018.11.002","article-title":"Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease","volume":"51","author":"Marais","year":"2019","journal-title":"Pathology"},{"key":"2022060112333135300_ref10","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/cvr\/cvz338","article-title":"Lipoprotein receptor signalling in atherosclerosis","volume":"116","author":"Mineo","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2022060112333135300_ref11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2021.05.007","article-title":"APOE gene variants in primary dyslipidemia","volume":"328","author":"Khalil","year":"2021","journal-title":"Atherosclerosis"},{"key":"2022060112333135300_ref12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11883-021-00933-4","article-title":"Apolipoprotein E and Atherosclerosis","volume":"23","author":"Marais","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"2022060112333135300_ref13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.arr.2017.06.002","article-title":"Evolution of human apolipoprotein E (APOE) isoforms: Gene structure, protein function and interaction with dietary factors","volume":"37","author":"Huebbe","year":"2017","journal-title":"Ageing Res Rev"},{"key":"2022060112333135300_ref14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.csbj.2017.05.003","article-title":"Apolipoprotein E - a multifunctional protein with implications in various pathologies as a result of its structural features","volume":"15","author":"Tudorache","year":"2017","journal-title":"Comput Struct Biotechnol J"},{"key":"2022060112333135300_ref15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0009-8981(99)00097-2","article-title":"Apolipoprotein E and atherosclerosis: insight from animal and human studies","volume":"286","author":"Davignon","year":"1999","journal-title":"Clin Chim Acta"},{"key":"2022060112333135300_ref16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/1076029612444002","article-title":"Genetic polymorphisms of HO-1 and COX-1 are associated with aspirin resistance defined by light transmittance aggregation in Chinese Han patients","volume":"19","author":"Li","year":"2013","journal-title":"Clin Appl Thromb Hemost"},{"key":"2022060112333135300_ref17","doi-asserted-by":"crossref","first-page":"13493","DOI":"10.1073\/pnas.1402106111","article-title":"Genetic variants of ApoE and ApoER2 differentially modulate endothelial function","volume":"111","author":"Ulrich","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060112333135300_ref18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/ATVBAHA.111.238964","article-title":"ApoE suppresses atherosclerosis by reducing lipid accumulation in circulating monocytes and the expression of inflammatory molecules on monocytes and vascular endothelium","volume":"32","author":"Gaudreault","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022060112333135300_ref19","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/ATVBAHA.111.222745","article-title":"Apolipoprotein E induces antiinflammatory phenotype in macrophages","volume":"31","author":"Baitsch","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022060112333135300_ref20","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMe1603504","article-title":"More HOPE for Prevention with Statins","volume":"374","author":"Cushman","year":"2016","journal-title":"N Engl J Med"},{"key":"2022060112333135300_ref21","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1001\/jama.298.11.1300","article-title":"Association of apolipoprotein E genotypes with lipid levels and coronary risk","volume":"298","author":"Bennet","year":"2007","journal-title":"JAMA"},{"key":"2022060112333135300_ref22","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.4103\/0366-6999.156803","article-title":"Meta-analysis for the association of apolipoprotein E \u03b52\/\u03b53\/\u03b54 polymorphism with coronary heart disease","volume":"128","author":"Zhang","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"2022060112333135300_ref23","doi-asserted-by":"crossref","first-page":"12222","DOI":"10.18632\/aging.103405","article-title":"ApoE e2 and aging-related outcomes in 379,000 UK Biobank participants","volume":"12","author":"Kuo","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"2022060112333135300_ref24","doi-asserted-by":"crossref","first-page":"102954","DOI":"10.1016\/j.ebiom.2020.102954","article-title":"Apolipoprotein E (APOE) genotype-associated disease risks: aphenome-wide, registry-based, case-control study utilising the UK Biobank","volume":"59","author":"Lumsden","year":"2020","journal-title":"EBioMedicine"},{"key":"2022060112333135300_ref25","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9082636","article-title":"Advances in Platelet Function Testing-Light Transmission Aggregometry and Beyond","volume":"9","author":"Le Blanc","year":"2020","journal-title":"J Clin Med"},{"key":"2022060112333135300_ref26","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/bph.14196","article-title":"Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond)","volume":"176","author":"Crescente","year":"2019","journal-title":"Br J Pharmacol"},{"key":"2022060112333135300_ref27","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"2022060112333135300_ref28","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/cvr\/cvab003","article-title":"The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis","volume":"117","author":"Badimon","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2022060112333135300_ref29","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf6054","article-title":"Endothelial cyclooxygenase-1 paradoxically drives local vasoconstriction and atherogenesis despite underpinning prostacyclin generation","volume":"7","author":"Mitchell","year":"2021","journal-title":"Sci Adv"},{"key":"2022060112333135300_ref30","doi-asserted-by":"crossref","first-page":"10027","DOI":"10.1096\/fj.202000312R","article-title":"Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin","volume":"34","author":"Crescente","year":"2020","journal-title":"FASEB J"}],"container-title":["Age and Ageing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/51\/6\/afac119\/43915553\/afac119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/51\/6\/afac119\/43915553\/afac119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T12:34:06Z","timestamp":1654086846000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ageing\/article\/doi\/10.1093\/ageing\/afac119\/6596556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ageing\/afac119","relation":{},"ISSN":["0002-0729","1468-2834"],"issn-type":[{"type":"print","value":"0002-0729"},{"type":"electronic","value":"1468-2834"}],"subject":[],"published-other":{"date-parts":[[2022,6]]},"published":{"date-parts":[[2022,6,1]]},"article-number":"afac119"}}